Phase 3 Win: Cretostimogene Cuts Bladder Cancer Recurrence Risk 68%
CGON has more than doubled off its 52-week low of $37.01 on elevated volume (3.3× avg).
Summary
PIVOT-006 hit its primary endpoint: cretostimogene cut the risk of recurrence by 68% versus surveillance after complete tumor resection, with a hazard ratio of 0.32 (p<0.0001) and median follow-up of 17 months. Safety was clean — no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. That matters because roughly 50,000 intermediate-risk and high-grade Ta NMIBC patients have no FDA-approved adjuvant option today, so a positive registrational readout here opens a second commercial market on top of the BCG-unresponsive franchise. Management now plans a second BLA in intermediate-risk and high-grade Ta disease in Q2 2027, and, following FDA feedback, will broaden the initial BCG-unresponsive BLA to include high-grade papillary-only disease, pushing that submission to before the end of March 2027. The company has about $984.5M in cash and $500M still available under its ATM, so funding the filings is not the constraint — execution and FDA review are. Topline data get a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026.
At the time of this announcement, CGON was trading at $100.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $37.01 to $80.97. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.